



## Principles and Codes Guiding DCVMN and its Representatives Circulated on 02<sup>nd</sup> October 2018

### Introduction and Background

The Developing Countries Vaccine Manufacturers Network (DCVMN) is a voluntary, public health-driven alliance of around 50 vaccine manufacturers, in 17 countries and territories, producing and supplying over 40 different types of vaccines, totaling around 200 products.

DCVMN supports its members through provision of information and professional training programs, monitoring technology improvements, supporting innovative vaccine research and development, encouraging technology transfer initiatives, and educating the public about the availability of safe, effective and affordable vaccines for all people.

DCVMN members share a mission to provide a consistent and sustainable supply of quality vaccines at affordable prices to developing countries – aligned with a vision of protecting all people against known and emerging infectious diseases.

Achieving this global public health vision depends on a consistent, and high degree of public trust and confidence in the vaccine enterprise. To secure and strengthen that trust and confidence, DCVMN and its **representatives** commit to operate under the highest ethical standards, all other relevant global standards, and the applicable laws and customs in countries where they operate. [Our values](#) of Equity, Responsibility, Accountability, Transparency and Respect are aligned to this commitment.

Following are selected principles and commitments related to important operational areas. These commitments apply specifically to DCVMN as an entity established in Switzerland, and to DCVMN **representatives**, whose own codes of ethics and responsible conduct further reflect their unique operating environments.

### Governance, Operational Integrity

DCVMN is governed by a democratically-elected, member-based Executive Committee [EC] which operates under applicable Swiss law and good-practice governance principles. The Executive Committee is responsible for fiscal stewardship and oversight of DCVMN operations and programs, robust decision-making, transparency, and assuring accuracy and compliance in all required financial, taxation and legal reporting.

Further, the Executive Committee and the DCVMN Secretariat work in concert to assure all business processes and practices are free from instances of undue influence or inducement, bribery, or corruption of any type. All Executive Committee members and Secretariat staff are required to immediately report any actual or perceived conflicts-of-interest [CIO]. The EC is charged with the immediate mitigation of any COI it encounters.

## **Research and Clinical Development Ethics and integrity**

DCVMN members develop and supply quality vaccines at affordable prices to developing countries. Vaccine development depends on the highest levels of ethical and research integrity across the full clinical development life cycle – from early discovery, through clinical trials, licensing and marketing approvals, manufacturing, marketing and distribution.

DCVMN is committed to promoting the rigorous design and careful implementation of research and clinical trials that meet or exceed global, national and other standards, including in all research conducted by Clinical Research Organizations or third parties. This commitment extends to accuracy and integrity regarding all regulatory filings and interactions, compliance with all relevant quality standards for manufacturing, and the accuracy of all required post-approval reporting.

Beyond its operations, DCVMN supports all efforts to strengthen international research integrity, assure scientific freedom and responsibility, and defend open scholarly communications everywhere.

## **Equality and Diversity, Human Rights, Modern Slavery**

In its hiring, management and promotion practices, DCVMN and **its representatives** are committed to equality and diversity. We celebrate differences, encourage diverse thinking and perspectives, and support gender-balanced professional growth opportunities for all.

As a global organization, DCVMN and **its representatives** support all efforts to eradicate forced labor and all forms modern slavery, identify and interdict trafficking in persons for any purpose, and to defend human rights for all peoples including

- Civil rights (such as the rights to life, liberty and security),
- Political rights (such as rights to the protection under and equality before the law),
- Economic rights (including right to work, to own property and to receive equal pay),
- Social rights (such as a right to education and information),
- Cultural rights (including the right to expression, and to freely participate in one’s community), and,
- Collective rights (such as the right to self-determination).

## **Personal responsibility**

DCVMN expects staff, board members, affiliates, and those with whom we work to conduct themselves with utmost integrity and in a manner that complies with the letter and spirit of all applicable laws and regulations. DCVMN expects each individual to know and understand what is expected for their particular role, to perform against that expectation, and to act with good judgment in all their actions – mindful that the public health mission of DCVMN depends on their personal and the network’s collective integrity.

# # # #

*Draft 2.1 of 24 Sep 2018: This draft is the work product of David R Curry and Paige Fitzsimmons of the GE2P2 Global Foundation, and benefitted from previous draft content developed by Sonia Pagliusi of the DCVMN.*



## About DCVMN

The Developing Countries Vaccine Manufacturers Network (DCVMN) was established in the year 2000, sharing the vision of protecting all people against known and emerging infectious diseases, with the mission of increasing the quality and availability of vaccines affordable to all. DCVMN is a public health driven, international alliance of manufacturers, working to strengthen vaccine manufacturers through the provision of information and professional training programs, technology improvements, innovative vaccine research and development, encouraging technology transfer initiatives, and educating the public about the availability of safe, effective and affordable vaccines for all people. Over the years the network grew reaching out today to include 50 vaccine manufacturers, in 17 countries and territories, producing and supplying over 40 different types of vaccines, in several presentations and using a variety of technology platforms totaling around 200 products. From those nearly 40 are prequalified by WHO.

*The Objectives of the Network are as follows:*

- To provide a consistent and sustainable supply of quality vaccines at an affordable price to developing countries

*The following are the ancillary objectives and goals:*

- To form a voluntary public health driven alliance of vaccine manufacturers from developing countries
- To strive for an International recognition such that developing country vaccine manufacturers have an essential role in assuring the availability of quality vaccines for national immunization programs
- To encourage continuation of Research and Development efforts to meet the emerging vaccine needs in the developing world.
- Foster the development of members of the network to attain the status of WHO pre-qualification
- Foster collaboration and communication amongst members of the network and actively participate in the international vaccine community to accomplish network specified goal.

## DCVMN: Our values

### **Equity**

We aim to maximize access to vaccines by making them affordable to all people, providing information and opportunities to all member companies from developing countries.

### **Responsibility**

Each and all of our activities aim to support achieving our common mission.

### **Accountability**

We strive to provide accurate reports and financial statements of our activities to all members.

### **Transparency**

We foster a culture of good governance based on collegial decision-making processes.

### **Respect**

Different opinions are welcome and respected.

## [DCVMN Members committed to boost global access to high-quality vaccines](#)

31 August 2015

Geneva 10h August 2015 - DCVMN Member companies have reached an understanding to cooperate in an effort to increase and maintain the number of WHO prequalified vaccines available for international procurement, and to achieve a more sustainable and secure supply of priority vaccines, as identified by global health agencies such as WHO, UNICEF and Gavi, the Vaccine Alliance. All corporate members are invited to join the effort.

The agreements highlight the principles of Global Access to ensure the development, manufacture and delivery of vaccines available and accessible in terms of quality, quantity and affordability to people in need in the developing world. For that purpose DCVMN members committed to Global Access to vaccines through a Memorandum of Understanding - between DCVMN and Member Companies - that provides a mechanism through which they can work together at both a strategic level and a specific project level.

DCVMN Member Companies share the common goal of protecting people from infectious diseases, by accelerating access to affordable high-quality vaccines: "Our focus is twofold: high-quality vaccines for all people and dialogue with stakeholders, to assist manufacturers in getting the knowledge, tools and skills required to attain and maintain WHO prequalification status giving access to priority vaccines", emphasized Mahendra Suhardono, President of the Network.

DCVMN Member companies [\[1\]](#) that committed to Global Access to Vaccines through a signed MOU to date include:

Arabio Co.  
Beijing Minhai Biotechnology Co. Ltd  
Bharat Biotech International Ltd  
Bio Farma PT  
Biological E Ltd  
Bio-Manguinhos Fiocruz  
BioNet-Asia Co. Ltd  
Biovac Institute  
BravoVax Co. Ltd  
Butantan Institute  
Cadila Biopharmaceuticals  
Changchun BCHT Biotechnology Co.  
China National Biotec Group Company Ltd  
EuBiologics Co. Ltd  
Finlay Instituto  
Fundacao Ataulpho De Paiva  
Incepta Vaccine Ltd  
Indian Immunologicals Ltd  
Laboratorios de Biologicos y Reactivos de Mexico S.A de C.V  
LG Life Sciences  
Liaoning ChengDa Biotechnology Co. Ltd (CDBIO)  
Medigen Vaccinology Corporation  
Panacea Biotec Ltd  
Pasteur Institute of Iran  
Polyvac  
Razi Vaccine & Serum Research Institute

Serum Institute of India Ltd (Poonawalla Group)  
Sinergium Biotech  
Sinovac  
Sk Chemicals  
Thai Red Cross Society- Queen Saovabha Memorial Institute  
The National Institute of Infectious Diseases and Vaccinology (NIIDV)  
The Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS)  
Tiantian Bio  
Vabiotech  
Vaccera  
VINS Bioproducts Ltd  
Walvax Biotechnology Co. Ltd  
Xiamen Innovax Biotech Co. Ltd

### [DCVMN International develops multiple initiatives to accelerate access to affordable high quality-vaccines](#)

19 November 2014

October 2014 — The Developing Countries Vaccine Manufacturers Network (DCVMN) International has announced at its annual gathering in Delhi, India, its intention to support access to affordable high-quality vaccines by enabling a larger number of vaccine manufacturers to achieve a more sustainable and secure supply of priority vaccines for international procurement, particularly for GAVI-eligible countries, with the common goal of protecting people against known and emerging infectious diseases globally.

DCVMN, through its members, has been working together with global health stakeholders since early this year, in identifying needs and challenges of the vaccine industry in developing countries. Four areas of action have been agreed to strengthen and foster sustainable vaccine supply: (1) review of manufacturing facilities design, (2) provide adequate training on evolving GMP requirements, quality management systems, and the WHO standards and prequalification, (3) encourage dialogue on regulatory challenges, (4) facilitate access to independent experts able to resolve vaccine industry specific issues. The three years' project costs of over 3.6 million dollars will be sourced to 60 percent by international global health organizations and the remaining jointly by DCVMN members and partners. The priority vaccines to be targeted encompass Pentavalent/Hexavalent, Pneumococcal Conjugate, Rotavirus, Typhoid Conjugate, Human Papillomavirus, Measles/Rubella and Inactivated Polio vaccines.

“Two out of three children in the world receive lifesaving vaccines from emerging manufacturers, and as the world’s population is growing at the fastest rate in developing countries, it is important to ensure improved manufacturing in every facility we can reach” said Mr. Mahendra Suhardono, President of DCVMN.

All members involved in funding these initiatives share the vision of developing countries free of suffering and disabilities from major infectious diseases, and will work together to foster the development and supply of safe, effective and affordable vaccines for the future generations of world’s developing nations.